184 related articles for article (PubMed ID: 28206956)
1. NF-κB1, c-Rel, and ELK1 inhibit miR-134 expression leading to TAB1 upregulation in paclitaxel-resistant human ovarian cancer.
Shuang T; Wang M; Zhou Y; Shi C; Wang D
Oncotarget; 2017 Apr; 8(15):24853-24868. PubMed ID: 28206956
[TBL] [Abstract][Full Text] [Related]
2. Over-expression of nuclear NF-κB1 and c-Rel correlates with chemoresistance and prognosis of serous epithelial ovarian cancer.
Shuang T; Wang M; Zhou Y; Shi C
Exp Mol Pathol; 2016 Feb; 100(1):139-44. PubMed ID: 26683819
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis.
Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092
[TBL] [Abstract][Full Text] [Related]
5. RSF1 is a positive regulator of NF-κB-induced gene expression required for ovarian cancer chemoresistance.
Yang YI; Ahn JH; Lee KT; Shih IeM; Choi JH
Cancer Res; 2014 Apr; 74(8):2258-69. PubMed ID: 24566868
[TBL] [Abstract][Full Text] [Related]
6. Dysregulation of lnc-SNHG1 and miR-216b-5p correlate with chemoresistance and indicate poor prognosis of serous epithelial ovarian cancer.
Pei ML; Zhao ZX; Shuang T
J Ovarian Res; 2020 Dec; 13(1):144. PubMed ID: 33302997
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-kappaB1.
Guo LM; Pu Y; Han Z; Liu T; Li YX; Liu M; Li X; Tang H
FEBS J; 2009 Oct; 276(19):5537-46. PubMed ID: 19702828
[TBL] [Abstract][Full Text] [Related]
8. lncRNA-PRLB Confers Paclitaxel Resistance of Ovarian Cancer Cells by Regulating RSF1/NF-κB Signaling Pathway.
Zhao Y; Hong L
Cancer Biother Radiopharm; 2021 Mar; 36(2):202-210. PubMed ID: 33156701
[No Abstract] [Full Text] [Related]
9. BAG3 upregulates Mcl-1 through downregulation of miR-29b to induce anticancer drug resistance in ovarian cancer.
Sugio A; Iwasaki M; Habata S; Mariya T; Suzuki M; Osogami H; Tamate M; Tanaka R; Saito T
Gynecol Oncol; 2014 Sep; 134(3):615-23. PubMed ID: 24992675
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.
Feng L; Shen F; Zhou J; Li Y; Jiang R; Chen Y
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32190895
[TBL] [Abstract][Full Text] [Related]
11. Down-regulated expression of miR-134 contributes to paclitaxel resistance in human ovarian cancer cells.
Shuang T; Wang M; Shi C; Zhou Y; Wang D
FEBS Lett; 2015 Oct; 589(20 Pt B):3154-64. PubMed ID: 26363097
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-503-5p Inhibits the CD97-Mediated JAK2/STAT3 Pathway in Metastatic or Paclitaxel-Resistant Ovarian Cancer Cells.
Park GB; Kim D
Neoplasia; 2019 Feb; 21(2):206-215. PubMed ID: 30622051
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-9 up-regulates E-cadherin through inhibition of NF-κB1-Snail1 pathway in melanoma.
Liu S; Kumar SM; Lu H; Liu A; Yang R; Pushparajan A; Guo W; Xu X
J Pathol; 2012 Jan; 226(1):61-72. PubMed ID: 22131135
[TBL] [Abstract][Full Text] [Related]
15. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
16. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
[TBL] [Abstract][Full Text] [Related]
17. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.
Li Z; Hu S; Wang J; Cai J; Xiao L; Yu L; Wang Z
Gynecol Oncol; 2010 Oct; 119(1):125-30. PubMed ID: 20624637
[TBL] [Abstract][Full Text] [Related]
18. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
[TBL] [Abstract][Full Text] [Related]
19. Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer.
Huh JH; Kim TH; Kim K; Song JA; Jung YJ; Jeong JY; Lee MJ; Kim YK; Lee DH; An HJ
Br J Cancer; 2013 Jul; 109(2):452-61. PubMed ID: 23807165
[TBL] [Abstract][Full Text] [Related]
20. The biphasic role of NF-kappaB in progression and chemoresistance of ovarian cancer.
Yang G; Xiao X; Rosen DG; Cheng X; Wu X; Chang B; Liu G; Xue F; Mercado-Uribe I; Chiao P; Du X; Liu J
Clin Cancer Res; 2011 Apr; 17(8):2181-94. PubMed ID: 21339307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]